Group 1 - The article presents the rankings of various securities firms in different research categories as part of the 23rd New Fortune Best Analyst Awards [1][2][3] - The rankings are based on a phased statistical result as of August 11, indicating that they are not final [1][2] - The categories include macroeconomic research, strategy research, fixed income research, and sector-specific research such as real estate, food and beverage, and healthcare [1][2][3][4] Group 2 - In the macroeconomic research category, the top firms include GF Securities, Huachuang Securities, and Shenwan Hongyuan Securities [1] - For strategy research, the leading firms are CITIC Securities, GF Securities, and Shenwan Hongyuan Securities [2] - In fixed income research, the top firms are Huatai Securities, Shenwan Hongyuan Securities, and GF Securities [3] Group 3 - The rankings for specific sectors show that in real estate, the top firms are Longjiang Securities, Shenwan Hongyuan Securities, and GF Securities [6] - In the food and beverage sector, the leading firms are GF Securities, Shenwan Hongyuan Securities, and CITIC Securities [9] - For healthcare, the top firms include Industrial Securities, CITIC Securities, and Tianfeng Securities [7]

中信建投证券股份有限公司 关于 宁夏英力特化工股份有限公司 向特定对象发行股票 发行过程和认购对象合规性的报告 保荐人（主承销商） 二〇二五年八月 深圳证券交易所： 经中国证券监督管理委员会（以下简称"中国证监会"） 《关于同意宁夏英力 特化工股份有限公司向特定对象发行股票注册的批复》（证监许可〔2024〕1749 号），同意宁夏英力特化工股份有限公司（以下简称"英力特"、 "发行人"或"公 司"）向特定对象发行股票的注册申请。 中信建投证券股份有限公司（以下简称"中信建投证券"、 "保荐人（主承销 商）"）作为英力特本次向特定对象发行股票（以下简称"本次发行"）的保荐人 和主承销商，对发行人本次发行过程及认购对象的合规性进行了核查，认为英力 特的本次发行过程及认购对象符合《中华人民共和国公司法》 （以下简称"《公司 法》"） 《中华人民共和国证券法》 （以下简称" 《证券法》"） 《深圳证券交易所股票 上市规则》 （以下简称"《上市规则》"） 《证券发行与承销管理办法》 《上市公司证 券发行注册管理办法》（以下简称"《注册管理办法》"）《深圳证券交易所上市公 司证券发行与承销业务实施细则》 （以下简称"《实 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 出品：新浪财经上市公司研究院 作者：IPO再融资组/郑权 2025年7月，A股IPO市场继续回暖。wind显示，7月共有8家企业完成IPO发行，募资总额达到241.64亿元，相较于2025年6月的91.53亿元增长了 164.3%。 被暂缓审议的企业是厦门恒坤新材料科技股份有限公司（简称"恒坤新材"），中信建投保荐。在2025年7月25日的上市委审核会议上，恒坤新材被暂 缓审议。在此之前，2025年以来共有19家券商保荐35家IPO企业上会且全部过会，过会率100%。 受理层面，在经历2025年6月的 "受理潮"（150家）后，7月A股 IPO 新增受理企业数量大幅减少，仅1家企业获得受理，为科创板的珠海泰诺麦博制 药股份有限公司。 审核方面，7月共有9 家拟IPO企业上会审核，8 家过会，1 家被暂缓表决，过会率88.89%，打破了上半年100%的过会率。7月份被暂缓表决的企业是 恒坤新材，保荐券商是中信建投。 终止层面，7月份共有6家企业终止IPO进程，较6月的10家有所下降。注册环节，7月A股IPO注册生效合计11家，单月批文数量 ...

博时、兴证全球APP上半年月活跃用户均减少超1万。南方基金、广发基金、中欧财富、汇添富现金 宝、鹏华A加钱包等APP也均出现不同程度下滑。 具体来看，广发基金APP在短暂触及8万月活跃用户后回落，上半年减少0.35万；汇添富现金宝从13.07 万的高点持续下滑至7.73万，或逼近盈利临界点；鹏华A加钱包月活跃用户仅余0.59万，日均活跃用户 不足两千；博时基金APP上半年月活跃用户减少1.78万，按最新2.03万的基数计算，前景不容乐观。 相比之下，券商类APP的同期月活数以"几十万"为底线，最差也在这一量级之上。 近日，平安基金宣布终止旗下APP运营，成为基金行业又一家选择关闭移动客户端的公司。自2019年信 达澳亚基金率先终止APP运营以来，中小公募基金公司缩减自营APP的趋势逐渐显现。过去一年间，前 海开源基金、国寿安保基金、财通基金、光大保德信基金、长盛基金等多家公募也已陆续关停其独立 APP业务。 净值萎缩、月活跃用户（MAU）下滑、运营规模过低，已成为基金APP面临的普遍压力。早期，基金 公司建设自有APP旨在掌握客户与数据，减少对第三方代销渠道的依赖。然而，当前情况已发生显著变 化——高昂的技术 ...

中 信 建 投 証 券 股 份 有 限 公 司（「 本 公 司 」）董 事 會（「 董 事 會 」）謹 此 宣 佈 ， 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不 對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何 損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6066） 董事會會議通告 中信建投証券股份有限公司 董事長 劉成 中國北京 於本公告日期，本公司執行董事為劉成先生及金劍華先生；本公司非執 行董事為李岷先生、閆小雷先生、劉延明先生、楊棟先生、華淑蕊女士 及王華女士；以及本公司獨立非執行董事為浦偉光先生、賴觀榮先生、 張崢先生、吳溪先生及鄭偉先生。 董 事 會 會 議 將 於 2 0 2 5 年 8 月 2 8 日（ 星 期 四 ）舉 行 ， 藉 以（ 其 中 包 括 ） 審 議 及批准本公司及其附屬公司截至2025年6月30日止六個月之中期業績及 其發佈。 承董事會命 ...

中 信 建 投 証 券 股 份 有 限 公 司（「 本公司 」）董 事 會（「 董事會 」）謹 此 宣 佈 ， 董事會會議將於 2025 年 8 月 2 8 日（ 星 期 四 ）舉 行 ， 藉 以（ 其 中 包 括 ）審 議 及批准本公司及其附屬公司截至 2025 年 6 月 3 0 日止六個月之中期業績及 其發佈。 承董事會命 中信建投証券股份有限公司 董事長 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6066） 董事會會議通告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不 對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何 損失承擔任何責任。 劉 成 中國北京 2025 年 8 月 8 日 於本公告日期，本公司執行董事為劉成先生及金劍華先生；本公司非執 行董事為李岷先生、閆小雷先生、劉延明先生、楊棟先生、華淑蕊女士 及王華女士；以及本公司獨立非執行董事為浦偉光先生、賴觀榮先生、 張崢先生、吳溪先生及鄭偉先生。 ...

Group 1: Core Insights - The third batch of "old-for-new" national subsidies has resumed application across various regions, with weekly data showing gradual improvement. Currently, the exemption for new energy vehicles is 30,000 yuan, which will be adjusted to half (15,000 yuan) in 2026-2027. This is expected to benefit strong new car cycles and high-end brands priced above 300,000 yuan [1] - The passenger car sector is experiencing a favorable product cycle due to reduced competition, allowing leading manufacturers to price new vehicles effectively. The launch of the JAC Refine S800 has seen over 10,000 orders within 76 days, indicating a blue ocean market for domestic high-end brands [2] - The L4 autonomous driving sector is at a turning point in terms of cost and technology, with the upcoming release of the L2 strong standard draft indicating national endorsement. This shift is expected to enhance the quantifiable brand power of intelligent vehicles [3] Group 2: Sector Performance - The robotics sector is maintaining a strong performance following the World Robotics Conference in 2025, with high market attention and strong individual stock movements. Companies entering the Tesla supply chain or representing technological advancements are likely to be favored by investors [4] - The bus and heavy truck sectors have seen significant growth in Q2, primarily due to increased exports. With domestic subsidies accelerating since May, both core sectors are expected to maintain strong fundamentals, with further growth anticipated in Q3 [5]

【导读】多家券商跻身上市公司前十大流通股东 见习记者 舍梨 （数据来源： Choice 终端） 具体来看，申万宏源证券、招商证券分别为藏格矿业第八大、第九大流通股东，且两家券商均在二季度加仓，加仓数量分别为 295.74 万股和 7.2 万股。截至二季度末，申万宏源证券持仓股份数增至 1811.81 万股，招商证券持仓股份数增至 1579.75 万 股。 国投证券新进成为华特达因第六大流通股东和西部矿业第十大流通股东，分别持股 2198 万股和 380.13 万股；上海证券新进成为 泰嘉股份第六大流通股东，持股数量为 180 万股；华泰证券新进成为凯美特气第十大流通股东，持股数量为 271.73 万股；财达 证券新进成为银河电子第四大流通股东，持股数量为 1319.99 万股。 从券商加仓情况看，民士达获开源证券加仓 3 万股，惠城环保获国联民生证券加仓约 0.14 万股。此外，也有一些上市公司，虽然 券商仍位列十大流通股东名单中，但在今年二季度有所减持，例如申万宏源减持约 52.28 万股湘电股份。 券商行业研究和市场分析功力较深厚，券商重仓股备受市场关注。 Choice 数据显示，截至 8 月 11 日， ...

Group 1 - The current market for small and micro-cap stocks needs to slow down, as high valuations and low profitability make it difficult to justify further upward movement [1] - The five strong industries (non-ferrous metals, telecommunications, innovative pharmaceuticals, gaming, and military industry) have more reasonable valuations compared to the small and micro-cap stocks [1] - The main drivers of small and micro-cap stock increases are liquidity and retail investor contributions, rather than structural earnings growth [1] Group 2 - A rebound in A-shares was observed, driven by trading funds, with a focus on themes and sectors that show improvement in earnings [2] - The PPI has reached a low point, indicating potential for price recovery in certain sectors, while the market is expected to experience rotation among sectors [3] - The liquidity environment is improving, supporting a high volatility market, with a focus on sectors like storage, software, and insurance for tactical allocation [4] Group 3 - The export sector showed unexpected improvement, particularly in competitive manufacturing areas like machinery and automotive [3] - The PPI's stability suggests a favorable environment for certain industries, with recommendations for sectors that are expected to see high growth in earnings [3] - The market is expected to maintain a high level of activity, with a focus on sectors benefiting from policy support and technological advancements [4] Group 4 - The current market is characterized by a "slow bull" trend, with potential for continued upward movement in A-shares driven by resident capital inflows [8] - The focus on new technologies and growth sectors is expected to remain a key theme, with recommendations for investments in areas like robotics and solid-state batteries [8] - The market is undergoing a structural shift rather than a complete downturn, with a gradual transition from traditional cyclical sectors to technology sectors [11]

Core Viewpoint - The Chinese medical device industry is transitioning from domestic substitution and penetration to internationalization and technological innovation, leading to a valuation reshaping as companies enhance their product competitiveness [1] Group 1: Industry Trends - The medical device sector has experienced a continuous decline from 2021 to 2024, but signs of a performance turning point are emerging in the second half of 2023 due to improved procurement policies and declining channel inventory [1] - High-value consumables are expected to see long-term penetration growth, while medical equipment is projected to stabilize and recover starting from Q4 2024 [1] - The in-vitro diagnostics (IVD) sector remains under pressure in the short term, but there is significant potential for domestic substitution in the medium to long term [1] Group 2: Company Strategies - Companies are focusing on cost reduction and efficiency improvement through automation and optimized production processes [2] - Strategic shifts include technological innovation and product differentiation to mitigate procurement risks, with expectations of favorable reimbursement policies for innovative devices [2] - Many companies are pursuing international expansion, leveraging supply chain advantages and stable pricing in overseas markets [2] Group 3: Innovation and Global Competitiveness - Chinese medical device companies are achieving global leadership in certain innovative products, such as the world's first full-body PET/CT and advanced chemical luminescence instruments [3] - The industry is witnessing a trend of mergers and acquisitions as companies seek new growth avenues amid limited domestic market ceilings [4] - The potential for license-out strategies is being explored to accelerate international market entry for innovative products [4] Group 4: Investment Opportunities - In the Hong Kong stock market, there are opportunities in companies with strong innovation capabilities and those poised for profitability recovery or high growth [6] - A focus on A-share companies that are expected to reach performance turning points and possess strong internationalization capabilities is recommended [7]